Leading Pharma and Research Organizations to Attend Genedata Screener Global User Group Meetings
Basel, Switzerland (PRWEB) May 16, 2017 -- Genedata, a leading provider of advanced software solutions for R&D, today announced its global Genedata Screener User Group Meetings, which will be held in Boston, Cambridge/UK, Shanghai, and Tokyo. These forums give Genedata Screener users the opportunity to share best practices in screening data analysis and learn about the latest advances in screening technologies and applications. They also enable customers to network with scientists and informaticians from some of the world’s premier pharmaceutical companies, academic research institutions, and contract research organizations. Scientists and researchers from Agios Pharmaceuticals, AstraZeneca, Biogen, Broad Institute, Constellation Pharmaceuticals, Daiichi Sankyo, EMD Serono, Evotec, MRC Technology, and UCB are among attendees at this year’s global User Group Meetings.
“Screener User Group Meetings are valuable knowledge-sharing events,” said Suvarna Khare-Pandit, a research scientist with Vertex Pharmaceuticals. “Agenda topics are comprehensive and balanced, giving you insights into how other researchers are using Screener. These meetings are a great opportunity to network with my peers and the Genedata Screener team.” At the Boston User Group Meeting (UGM), Khare-Pandit will deliver a presentation on how Vertex uses Genedata Screener for assay validation and compound screening with high-content image data analysis.
Customer Collaboration Key to Innovation
“Close collaborations and regular discussions with customers are part of the Genedata DNA,” said Dr. Othmar Pfannes, CEO of Genedata. “This level of engagement enables us to acquire a deeper understanding of our customers’ requirements so that we can continuously develop better solutions that keep us at the frontier of science and technology.”
Regional and accessible, Genedata Screener UGMs promote dialogue between screening sciences and data sciences. They also provide an opportunity to share insights on current and future functionality in Genedata Screener. For example, Relay Therapeutics will detail how it uses Genedata Screener in the cloud to enhance collaborative research and screening data analysis. Other presentations will address Genedata Screener applications in areas such as Automated Patch Clamp (APC), Compound Combination Screening, High Content Screening (HCS), and Surface Plasmon Resonance (SPR).
Editorial Note: The following are among the customer presentations that will be featured at global UGMs:
• Relay Therapeutics: Implementing Genedata Screener in a Cloud-based Informatics Platform (Boston)
• Vertex: Assay Validation and Compound Screening with High Content Image Data Analysis Using Genedata Screener (Boston)
• AstraZeneca: AstraZeneca/ Genedata Co-development on the APC Parser and the AT50/80 Kinetic Analysis Using hERG, Screener Implementation for Routine Assay Development and Profiling (Cambridge/UK)
• MRC Technology: Drug Combinations as Potential Oncology Therapeutics: Data Analysis with Genedata Screener(Cambridge/UK)
• Philip Morris International: Overview of a Compound Profiling Workflow (Cambridge/UK)
Genedata Screener Global UGM Schedule
• Boston, USA: May 22 – Boston Museum of Science
• Shanghai, China: June 7 – Parkyard Hotel
• Cambridge, UK: June 20 – Granta Park
• Tokyo, Japan: September 7 – Tokyo Conference Centre Shinagawa
About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US. http://www.genedata.com. Follow Genedata on LinkedIn
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Jackie Thrasivoulos, Genedata Screener Public Relations, http://www.genedata.com, +1 5083806408, [email protected]
Share this article